Summary
Thermo Fisher Scientific Inc. announced on September 13, 2017, that its wholly owned subsidiary, Thermo Fisher (CN) Luxembourg S.à r.l., did not extend the subsequent offering period of its tender offer for Patheon N.V. shares. This effectively means the tender offer has expired without the company acquiring all outstanding shares of Patheon N.V. through this specific offer mechanism. The company issued a press release detailing the expiration and results of the tender offer.
Key Highlights
- 1Thermo Fisher Scientific (TMO) subsidiary's tender offer for Patheon N.V. shares expired.
- 2The subsequent offering period for the tender offer was not extended.
- 3The company did not proceed with acquiring all outstanding shares of Patheon N.V. via this tender offer.
- 4A press release was issued on September 13, 2017, to announce the tender offer results.
- 5This filing primarily serves to report the expiration of the tender offer and its associated press release.
Frequently Asked Questions
The main purpose of this 8-K filing was to formally announce the expiration of the tender offer by Thermo Fisher Scientific's subsidiary for Patheon N.V. shares and to include the accompanying press release as an exhibit.
Based on this filing, the tender offer expired and the subsequent offering period was not extended, indicating that Thermo Fisher Scientific did not acquire all outstanding shares of Patheon N.V. through this specific tender offer mechanism as initially intended or hoped.
A subsequent offering period is a limited additional period after the initial tender offer period expires, during which remaining shareholders can still tender their shares, typically on the same terms as the original offer. In this case, Thermo Fisher's subsidiary chose not to extend this period.